Agios Pharmaceuticals Inc. (0HB0)
Summary
0HB0 Chart
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Agios Pharmaceuticals Inc. (0HB0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Agios Pharmaceuticals Inc. ever had a stock split?
Agios Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Goff CEO | LSE Exchange | 00847X104 CUSIP |
| US Country | 540 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Agios Pharmaceuticals, Inc., established in 2007 and based in Cambridge, Massachusetts, is a pioneering biopharmaceutical company. It focuses on the discovery and development of novel medications targeting cellular metabolism for the treatment of various diseases in the United States. By leveraging its expertise in the field of cellular metabolism, Agios is dedicated to advancing a diverse pipeline of therapeutic candidates aimed at addressing unmet medical needs.
Products and Services
- PYRUKYND (mitapivat): An innovative activator of both wild-type and mutant forms of the pyruvate kinase (PK) enzyme. This flagship product by Agios Pharmaceuticals, Inc. is designed for the treatment of hemolytic anemias, a group of disorders characterized by the premature destruction of red blood cells, leading to a deficiency in healthy red blood cells in the body. Mitapivat has shown promise in addressing the underlying metabolic dysfunctions found in these conditions.
- AG-946: Another PK activator in the company’s robust pipeline, AG-946 is currently being developed as a potential therapeutic option for patients with lower-risk myelodysplastic syndrome (MDS) and hemolytic anemias. By targeting PK, this compound aims to correct metabolic irregularities that contribute to the pathology of these disorders, offering hope for improved treatments.
- AG-181: A phenylalanine hydroxylase stabilizer being explored for its potential in treating phenylketonuria (PKU). PKU is a metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, leading to high levels of phenylalanine in the blood, which can result in a variety of health problems. AG-181 aims to stabilize the enzyme, thereby reducing phenylalanine levels and mitigating the symptoms associated with PKU.
- siRNA Therapy for Polycythemia Vera: In its preclinical development stage, Agios is also investigating a small interfering RNA (siRNA) therapy targeting polycythemia vera, a rare blood disorder characterized by an overproduction of red blood cells. This innovative approach aims to silence specific gene expressions, offering a novel therapeutic pathway for managing this condition.
